FDA approves first of two UCB myasthenia gravis drugs, following Alexion and argenx’s lead
The FDA approved UCB’s generalized myasthenia gravis treatment Rystiggo, with the Belgian drugmaker saying it is the first drug to get OK’d for the two main subtypes of the rare autoimmune disease.
UCB said Tuesday that the under-the-skin treatment, known investigationally as rozanolixizumab-noli, will be commercially available in the third quarter. It follows the nod last week for argenx’s Vyvgart Hytrulo in subcutaneous form. That therapy was initially given the thumbs-up as an injectable in 2021.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
